|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 19, 2015 ) Dallas, TX -- The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%. There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immuno suppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications.
This report states that the US will continue to account for almost all of the celiac disease therapeutics space, which also includes the five European countries (5EU) of France, Germany, Spain, Italy and the UK. The US share will slip slightly from 99% in 2013 to just under 98% by the end of the forecast period. The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population. Complete report details available @ http://www.rnrmarketresearch.com/opportunityanalyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023-market-report.html .
Key questions answered cover by this report include: How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM?; What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market?; How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?; What are the significant unmet needs in the celiac disease market?; What are the remaining opportunities in the celiac disease market?
Key Findings cover by this report are: High uptake is expected of pipeline drugs for celiac disease that are anticipated to launch during the 2013-2023 forecast period.; Celiac disease remains a field of highly unattained unmet need.; There is no consensus over clinical trial design and endpoints for the development of celiac disease products.; The clinical stage pipeline is mainly focussed on GFD adjunctive therapies, while the pre-clinical stage pipeline has shifted its focus to disease modifying treatments.; Significant opportunity exists for products targeting in the non-refractory patient segment of the celiac disease market.; M&A’s and alliance opportunities will be key factors in driving celiac disease drug development. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=303180 . (This is a premium report priced at US$7995 for a single user License.)
In Q1 2019, larazotide acetate is expected to launch in the 5EU, while latiglutenase may potentially launch in the US. These pipeline drugs are forecast to increase sales in the six major markets (6MM) from $49.6 million in 2013 to $289.9 million by the end of 2019
List of Tables
Table 1: Symptoms of Celiac Disease
Table 2: Risk Factors for Celiac Disease
Table 3: Studies Reporting Temporal Trends for Celiac Disease and Calculated Rate of Change
Table 4: 6MM, Sources of Prevalence and Diagnosis Rates of Celiac Disease
Table 5: 6MM, Sources Not Used in Epidemiological Forecast for Celiac Disease
Table 6: 6MM, Total Prevalent Cases of Celiac Disease, Both Sexes, All Ages, N, Select Years 2013–2023
Table 7: 6MM, Age-Specific Total Prevalent Cases of Celiac Disease, Both Sexes, N (Row %), 2013
Table 8: 6MM, Sex-Specific Total Prevalent Cases of Celiac Disease, All Ages, N (Row %), 2013
Table 9: 6MM, Diagnosed Prevalent Cases of Celiac Disease, Both Sexes, All Ages, Select Years 2013–2023
Table 10: Treatments for Celiac Disease, 2014
Table 11: Product Profile – Steroids
Table 12: Steroids SWOT Analysis, 2013
Table 13: Product Profile – Azathioprine
Table 14: Azathioprine SWOT Analysis, 2013
Table 15: Unmet Need and Opportunity in Celiac Disease
Table 16: Celiac Disease Pipeline, 2014
Table 17: Product Profile – Larazotide Acetate
Table 18: Summary of Clinical Trials for Larazotide Acetate in Celiac Disease, 2014
Table 19: Larazotide Acetate SWOT Analysis, 2014
Table 20: Product Profile – Latiglutenase
Table 21: Latiglutenase SWOT Analysis, 2014
Table 22: Product Profile – BL-7010
Table 23: BL-7010 SWOT Analysis, 2014
Table 24: Product Profile – NexVax-2
Table 25: NexVax-2 SWOT Analysis, 2014
Explore more reports on Autoimmune Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/autoimmune-drugs .
RnR Market Research
Ritesh Tiwari
+18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
